We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
+7.48%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$18.2M
AUM Growth
-$64.7M
Cap. Flow
-$60.1M
Cap. Flow %
-329.43%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$35.5M
2
VYGR icon
Voyager Therapeutics
VYGR
+$24.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DBTX
1
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$12.1M 66.29%
3,139,685
– –
PLRX icon
2
Pliant Therapeutics
PLRX
$65M
$6.15M 33.71%
339,160
-1,500,000
-82% -$35.5M
VYGR icon
3
Voyager Therapeutics
VYGR
$189M
– –
-3,185,291
Closed -$24.6M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q2 2023 Portfolio in Review

As of Q2 2023, TRV GP III held 3 positions worth $18.2M, down 78% from $83M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP III withdrew a net $60.1M in Q2 2023, closing 1 position and reducing 1 holding. Its most notable exit was Voyager Therapeutics, an estimated $24.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP III's biggest Q2 2023 reduction was Pliant Therapeutics, cutting an estimated $35.5M.
  • TRV GP III fully exited Voyager Therapeutics in Q2 2023, selling an estimated $24.6M.
  • TRV GP III's ten largest holdings make up 100% of its $18.2M portfolio in Q2 2023.
  • TRV GP III opened 0 new positions and closed 1 in Q2 2023.
  • TRV GP III's portfolio value fell 78% quarter-over-quarter to $18.2M.

Based on TRV GP III's 13F filing for Q2 2023, filed 10 Aug 2023.